NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will participate at the following investor events in August and September.
8th Annual Solebury Trout Hamptons CEO Roundtable
August 16, 2018
Graham Lumsden, Chief Executive Officer, will make a presentation on the Company and its product candidate, iclaprim, for which a New Drug Application (NDA) has recently been submitted. Motif Bio will also participate in one-on-one meetings during the event.
H.C. Wainwright 20th Annual Global Investment Conference
READ FULL TEXT